| Title |
Management of Secondary Progressive Multiple Sclerosis: Prophylactic Treatment—Past, Present, and Future Aspects
|
|---|---|
| Published in |
Current Treatment Options in Neurology, April 2013
|
| DOI | 10.1007/s11940-013-0233-x |
| Pubmed ID | |
| Authors |
Paulus S. Rommer, Olaf Stüve |
| Abstract |
Whereas the number of treatment options in relapsing-remitting multiple sclerosis (RRMS) is growing constantly, alternatives are rare in the case of secondary-progressive multiple sclerosis (SPMS). Besides mitoxantrone in North America and Europe, interferon beta-1b and beta-1a are approved for treatment in Europe. Glucocorticosteroids, azathioprine, intravenous immunoglobulins (IVIG) and cyclophosphamide (CYC), although not approved, are commonly utilized in SPMS. Currently monoclonal antibodies (mab), and masitinib are under examination for treatment for SPMS. Hematopoietic stem cell transplantation and immunoablative stem cell transplantation are therapies with the aim of reconstitution of the immune system. This review gives information on the different therapeutics and the trials that tested them. Pathophysiological considerations are presented in view of efficacy of the therapeutics. In addition, therapeutics that showed no efficacy in trials or with unacceptable side effects are topics of this review. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 67 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 1 | 1% |
| Turkey | 1 | 1% |
| United States | 1 | 1% |
| Netherlands | 1 | 1% |
| Unknown | 63 | 94% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 10 | 15% |
| Student > Master | 9 | 13% |
| Other | 7 | 10% |
| Student > Doctoral Student | 6 | 9% |
| Student > Postgraduate | 6 | 9% |
| Other | 19 | 28% |
| Unknown | 10 | 15% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 30 | 45% |
| Agricultural and Biological Sciences | 7 | 10% |
| Neuroscience | 5 | 7% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 4% |
| Immunology and Microbiology | 3 | 4% |
| Other | 6 | 9% |
| Unknown | 13 | 19% |
Attention Score in Context
This research output has an Altmetric Attention Score of 16. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 28 July 2020.
All research outputs
#1,935,624
of 22,709,015 outputs
Outputs from Current Treatment Options in Neurology
#33
of 468 outputs
Outputs of similar age
#16,982
of 195,119 outputs
Outputs of similar age from Current Treatment Options in Neurology
#2
of 12 outputs
Altmetric has tracked 22,709,015 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 91st percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 468 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.2. This one has done particularly well, scoring higher than 92% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 195,119 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 91% of its contemporaries.
We're also able to compare this research output to 12 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 83% of its contemporaries.